Disease × agent evidence record

Oxaliplatin for Lung Cancer: evidence, trials and status

Oxaliplatin has both completed registered trials and synthesis-level publications linked to Lung Cancer. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit.

8 registered trials 3 recruiting 16 publications Evidence tier A · Strong Score 70.5
Research Tracker › Pairs › Lung Cancer › Oxaliplatin
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

Oxaliplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Lung Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Lung Cancer. ClinicalTrials.gov lists 8 registered trials linking Oxaliplatin to Lung Cancer: 3 are currently recruiting; 1 is active or not yet recruiting; 2 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 1 (NCT06131840). It plans or enrolled 914 participants. Registration activity spans 2017 to 2025. The literature layer holds 16 publications for this pair: 3 Cochrane reviews, 4 meta-analyses, 1 systematic review, 3 randomised controlled trial publications and 5 clinical trial publications. Publication years run from 1997 to 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.

The RepurpOS disease-intelligence file for Lung Cancer ranks 465 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for stage I-II with surgery.

Open in Repurposing ExplorerLung Cancer hubLung Cancer biomarkers & interventions

Evidence table

Evidence tierA · Strong
Evidence score70.5 (trials 20.5, literature 30.0, tier 15, approved bonus 5.0)
Registered trials8 total: 3 recruiting, 1 active / not yet recruiting, 2 completed, 2 other
Linked publications16 (5 clinical trial publications, 4 meta-analyses, 3 Cochrane reviews, 3 randomised controlled trial publications, 1 systematic review)
Agent typeDrug (Small molecule)
Development stage (any indication)Approved
Mechanism / classNot recorded
Data sourcesDGIdb
Linked via biomarker / targetBRCA1
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

NCT IDTitleStatusPhaseEnrolment
NCT05867121A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
2023
completedPhase 1102
NCT03250832Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
2017
completedPhase 1111
NCT06131840A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
2023
recruitingPhase 1914
NCT06835569A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
2025
recruitingPhase 1448
NCT05576077A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
2023
terminatedPhase 131
NCT04043195Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
2019
active, not recruitingPHASE1, PHASE230
NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
2023
recruitingPHASE1, PHASE2134
NCT03009058Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
2017
terminatedPHASE1, PHASE22

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

No mechanism of action is recorded for this pair in the source databases.

OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.

Frequently asked questions

Is Oxaliplatin approved for Lung Cancer?

Oxaliplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Lung Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Lung Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is Oxaliplatin in clinical trials for Lung Cancer?

ClinicalTrials.gov lists 8 registered trials linking Oxaliplatin to Lung Cancer: 3 are currently recruiting; 1 is active or not yet recruiting; 2 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 1 (NCT06131840). It plans or enrolled 914 participants. Registration activity spans 2017 to 2025.

What does the evidence show for Oxaliplatin in Lung Cancer?

Oxaliplatin has both completed registered trials and synthesis-level publications linked to Lung Cancer. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.

Cite this page

Open Source Medicine Foundation. Oxaliplatin for Lung Cancer: evidence, trials and status. OSMF Research Tracker. Updated 2026-07-05. https://research.opensourcemed.info/pairs/lung-cancer/oxaliplatin.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.